AAV Capsid Analysis Resource
Mass photometry is the practical choice for rapid, low-volume AAV capsids screening, frequent measurements, and in-process monitoring, while analytical ultracentrifugation (AUC) is preferred for high-resolution characterization, release testing, orthogonal validation, and cases requiring the clearest separation of empty, partial, full, and overfull capsids. Because mass photometry provides results in about one minute from 10–20 µL and AUC offers deeper population-level resolution with greater time and sample requirements, combining both methods creates a more reliable analytical strategy across AAV process development and quality control.
Direct Answer
A real AAV preparation is a heterogeneous population. Empty capsids, partially filled capsids, full capsids carrying the intended genome, and overfull particles commonly coexist, and their proportions reflect the performance of transfection, production, and purification. Because these species differ in potency, consistency, and safety, characterization is the eye through which the whole process is watched—not simply a final release check.
The practical challenge is speed. If a measurement takes hours and consumes hundreds of microliters, it arrives too late to influence the very process it describes. AAV capsid content analysis must therefore be fit-for-purpose at every stage, from early production development through release.
The key principle: no single method is best for every question. The goal is to match each analytical tool to a decision window and to use complementary methods orthogonally, rather than forcing one instrument to answer everything.
Empty capsids add protein load without therapeutic benefit and can complicate dosing, immunogenicity, and clearance.
Partially filled capsids carry sub-genomic or truncated sequences, reducing the fraction of the dose that is actually functional.
Full capsids contain the complete therapeutic genome and are the species that most directly reflects potency and dose.
Overfull particles package more than one genome and can distort both identity and potency measurements if not resolved.
Method Comparison
Analytical ultracentrifugation, mass photometry, and anion-exchange chromatography each illuminate capsid content differently. Their value depends on resolution, throughput, sample consumption, and where they sit in the development lifecycle.
| Attribute | SV-AUC (Gold Standard) | Mass Photometry (MP) | AEX Chromatography |
|---|---|---|---|
| Measurement time | >6 hours per single SV-AUC run | ~1 minute per measurement | Minutes to tens of minutes per run |
| Sample volume | ~400 µL | ~10–20 µL | Larger volumes depending on setup |
| Concentration requirement | Micromolar | Nanomolar | Moderate to high |
| Resolution of capsid species | Excellent; resolves empty (~60–64 S), partial, and full (~100 S) | Distinguishes empty, partial, full, and overfull by single-particle mass | High throughput but limited for partial capsids |
| Expertise needed | Specialized operation and analysis | New users often up to speed within half a day | Moderate; familiar in many QC labs |
| Readout type | Population average | Single-particle counting with molar proportions | Chromatographic separation profile |
| Best role | High-fidelity, orthogonal characterization and release | High-frequency process development and in-process monitoring | High-throughput screening where partial-capsid resolution is less critical |
Head-to-head data support the correlation between MP and AUC. A 2023 study reported a linear relationship with R² = 0.9949 for full-capsid fraction, and a 2025 Regeneron comparison concluded that AEX offers high throughput but weak partial-capsid resolution, AUC offers the best resolution at low throughput, and MP balances both. Creative Biolabs applies these tools within a broader viral vector analysis program.
Faster Feedback
The value of MP is not that it replaces a slower method with a faster one, but that it turns a scarce, end-of-process measurement into a routine, early-stage one. That shift changes the questions a team can ask.
Compare transfection conditions and production parameters for packaging efficiency, not just total titer.
Track capsid distribution across fractions in real time to catch full-capsid losses early.
Ten microliters supports many rounds of screening even for precious early material.
More frequent measurement surfaces process drift before it compromises an expensive batch.
Reserve AUC for release and orthogonal validation, not for every process question.
Method Design
Both AUC and MP depend on sample handling and calibration. These variables should be controlled so that the reported empty/full fractions reflect the sample, not the method.
Buffer composition, dilution, and aggregation state can shift the measured population. Minimize handling and control matrix consistently.
MP mass calibration and AUC reference standards should be run with every study to keep single-particle mass assignments reproducible.
Different serotypes and fill states produce overlapping mass or sedimentation windows; ensure resolution before relying on a single threshold.
Freeze–thaw, agitation, and thermal stress change capsid populations; use controlled stress studies to validate method discrimination.
Choose MP for high-frequency screening and AUC for terminal or orthogonal readouts to keep both resolution and speed where they matter.
MP is increasingly recognized—referenced by USP, the British Pharmacopoeia, and ISO 16921-2—as a viable capsid-content method.
Decision Framework
MP will not replace AUC, and it does not need to. The practical strategy is to deploy MP for high-frequency, low-volume process decisions and to reserve AUC for the points where maximum resolution and long-standing precedent matter most.
Choose MP: when comparing many constructs, conditions, or time points and sample volume is limited.
Decision supported: fast ranking of packaging efficiency before committing resources.
Choose MP: to assess each fraction as purification runs, catching full-capsid loss in real time.
Decision supported: real-time process control and yield optimization.
Choose AUC: for high-fidelity, precedent-backed capsid-content determination at critical nodes.
Decision supported: release specifications and cross-validation of MP results.
Choose both: use MP for broad condition screening and AUC to confirm population shifts with maximum resolution.
Decision supported: comparability and forced-degradation assessments with orthogonal confirmation.
Choose AUC: when partial versus full distinction must be made with the highest confidence and AEX falls short.
Decision supported: high-fidelity identity, purity, and potency linkage.
Strategy Outputs
Each capsid-content result is mapped to a defined development role.
Full-capsid fraction across conditions.
In-process capsid distribution tracking.
Orthogonal confirmation and specifications.
MP for speed, AUC for resolution.
From Question to Evidence
Creative Biolabs can integrate capsid-content analysis into your AAV program, connecting production, purification, titration, and characterization in a single, decision-ready workflow.
Resolve empty, partial, full, and overfull capsids with a method matched to your decision window. This alignment supports rapid batch screening and focused confirmation of borderline or high-impact results.
Pair capsid-content data with genome copy number and infectious titer for a complete potency picture. Comparing these readouts distinguishes particle abundance from the fraction capable of genome delivery and biological activity.
Quantify empty-capsid burden and residual impurities that affect safety and dosing. The combined profile indicates whether nonproductive particles or contaminants could distort dose selection and study interpretation.
Optimize downstream steps using fast capsid-content feedback to protect full-capsid yield. Trend data can reveal which process changes improve packaging quality without sacrificing overall vector recovery.
Translate capsid-content insight into production decisions from early development onward. Applying consistent quality signals across runs helps identify process drift and prioritize conditions for scale-up.
Selected Reading
Wagner C, et al. Quantification of Empty, Partially Filled and Full Adeno-Associated Virus Vectors Using Mass Photometry. International Journal of Molecular Sciences. 2023;24(13):11033. View article.
Townsend J, et al. Comparative analysis of empty and full adeno-associated viruses under stress conditions by AEX, AUC, and mass photometry. Journal of Pharmaceutical Sciences. 2025. View article.
Gálvez-Montes C, et al. rAAV production cost analysis: indication-specific cost per dose and reduction strategies. Gene Therapy. 2026. View article.
FAQ
Tell us about your project, and our experts will get back to you with a customized quote and proposal.
